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Purpose: To our knowledge, no study has examined in a structured way the extent
of underprescription of clozapine in ambulatory patients with Non-Affective Psychotic
Disorder (NAPD). In the Netherlands, psychiatric care for such patients is provided by
Flexible Assertive Community Treatment (FACT) teams and by early intervention teams.
In 20 FACT teams and 3 early intervention teams we assessed the proportion of patients
who: use clozapine (type 1 patients), previously used this drug (type 2), have an unfulfilled
indication for this drug, by type of indication (type 3), or were at least markedly psychotic,
but had not yet received two adequate treatments with other antipsychotic drugs
(type 4). We expected to find major differences between teams. To rule out that these
differences are caused by differences in severity of psychopathology, we also calculated
the proportions of patients who use clozapine given an indication at any time (number of
type 1 patients divided by the sum of type 1, 2, and 3 patients).
Materials and methods: The nurse practitioner of each team identified the patients
already on clozapine. Next, using a highly-structured decision tree, the nurse practitioner
and psychiatrist assessed whether the remaining patients had an indication for this drug.
Indications were treatment-resistant positive symptoms, tardive dyskinesia, aggression
and suicidality. The severity of positive symptoms was determined using the Clinical
Global Impression-Schizophrenia Scale (CGI-SCH).
Results: In the participating FACT-teams 2,286 NAPD patients were assessed. The
range among teams in proportions was: type 1: 8.8–34.7% (mean: 23.0%), type 2:
0–8.2% (mean: 3.5%), type 3: 1.7–15.6% (mean: 6.9%), type 4: 1.8–16.3% (mean:
8.6%). The range in proportions of patients using this drug given an indication was
49.0–90.9% (mean: 68.8%). These figures were lower in early intervention teams.
Conclusions: The proportion of patients in FACT-teams who have an unfulfilled
indication for clozapine is 6.9%. There were considerable differences between teams
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with respect to this proportion. Almost a third of the outpatients had at any time an
indication for clozapine. If one takes type 4 patients into account, this proportion may
be higher.
Registration number: NTR5135 http://www.trialregister.nl/trialreg/index.asp
Keywords: clozapine, psychotic disorders, outpatient care, prescription rates, treatment resistance
INTRODUCTION
Despite the general idea that clozapine is underutilized, little
research has been done into the extent of this problem. The main
indication for this drug according to guidelines is treatment-
resistant schizophrenia, the prevalence of which has been
estimated at about 20–30% (1), but exact numbers are unknown.
This uncertainty is not only caused by a scarcity of pertinent
studies, but also by the absence (until recently) of consensus
on criteria to define treatment-resistant schizophrenia (2). To
illustrate this, Juarez-Reyes et al. (3) found that the proportion in
a population of outpatients was 12.9% with a stringent definition
and 42.9% with a broad definition. A Danish register-based study
among outpatients with a diagnosis of schizophrenia found a
prevalence of 24.7 or 48.2% (4), depending on the definition of
a proxy for treatment-resistant schizophrenia: (1) at least two
different periods of antipsychotic use and one hospitalization
within 18 months and (2) patients treated with polypharmacy
for at least 90 days. No information on adherence and symptom
severity was available, which precludes an exact assessment of
treatment-resistant schizophrenia.
Furthermore, there are also other indications for clozapine,
as it has been found to decrease tardive dyskinesia (5), acute
extrapyramidal symptoms (i.e., parkinsonism, acute dystonia,
and akathisia) (6), aggression (7–9), suicidality (10, 11), and
substance abuse (12). The prevalence of these other indications
is even more uncertain.
Studies of clozapine prescription rates show large
international differences (13–15). In the Netherlands, the
proportion of patients with Non-Affective Psychotic Disorder
(NAPD) using this drug is unknown. The vast majority of
them is treated on an ambulatory basis by Flexible Assertive
Community Treatment (FACT) teams and in some regions also
by early intervention teams. FACT-teams take care of patients
with a severe mental illness and are called “flexible” because they
intensify treatment when the patient is in a crisis, with the aim
to prevent hospitalization (16). These teams are responsible for
a certain area and treat approximately 200 outpatients, most
of whom with NAPD. Some institutes deploy specialized early
intervention teams to treat patients in the first years after onset
of psychosis. These teams work in the same way as the FACT-
teams, but they spend more time on diagnosing patients and
providing psychoeducation. Their caseloads may be smaller and
the patients are younger. After a maximum of 5 year, treatment
will be continued by a FACT-team. In general, in every FACT or
early intervention team there is a psychiatrist, but only part of
the teams have a nurse practitioner associated with it.
Summarizing, little is known about the magnitude of
underprescription of clozapine in outpatients with NAPD in
the Netherlands. We set out to examine in a structured
way rates of prescription and underprescription in FACT
teams and in early intervention teams. We developed a
decision tree with criteria for an indication for clozapine.
Our definition of treatment resistance differs only slightly
from the consensus guideline that was published shortly after
we collected our data (17). Since in our experience there
are major regional and personal differences in adherence
to guidelines regarding clozapine prescription, we expected
considerable differences between teams in proportions of
patients using this drug and patients with an unfulfilled
indication. In order to exclude the possibility that these
differences are solely caused by differences in the severity of
psychopathology, we calculated for each team the proportion
of patients who use clozapine given an indication at any
time.
The aims of this study were to determine prescription
rates and the extent of underprescription of clozapine in
outpatients with NAPD. We therefore assessed the proportions
of patients who (i) currently use clozapine (type 1 patients);
(ii) had used this drug and subsequently discontinued it
(type 2 patients); (iii) have an indication for this drug but
have never used it, by type of indication (type 3 patients);
(iv) were at least markedly psychotic, but had not yet received
two adequate treatments with antipsychotic drugs (type 4
patients); (v) currently use clozapine among patients with
an indication for this drug at any time (number of type 1
patients divided by the sum of type 1, type 2, and type 3
patients).
MATERIALS AND METHODS
Study Design and Setting
This study reports the results of baseline measurements
preceding a randomized controlled trial to assess the safety
of the deployment of nurse practitioners to start patients
on clozapine. Therefore, in this study, only teams with a
nurse practitioner associated with it were included. Twenty
FACT teams and three early intervention teams, from four
Dutch psychiatric institutes, participated. Each institute
deploys several teams, housed in the same building or at
miles distance from each other. In all participating teams,
the psychiatrist was responsible for the prescription of
antipsychotic drugs. Data was collected from July 2015 to
May 2016.
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Measures
According to Dutch guidelines (18, 19), clozapine is indicated
for patients with a diagnosis of schizophrenia or schizoaffective
disorder, who suffer from (1) treatment-resistant positive
or negative symptoms, (2) severe aggressive behavior,
(3) persistent suicidal behavior, (4) tardive dyskinesia,
(5) treatment-resistant acute extrapyramidal symptoms,
and (6) alcohol or drug abuse (18). However, since the current
evidence to support the use of clozapine for treatment-
resistant negative symptoms or substance abuse is insufficient,
this study did not regard these features as indications for
clozapine.
In order to structure the assessment of an indication for
clozapine, we developed a decision tree (see Appendix). Positive
symptoms were scored using the Clinical Global Impression-
Schizophrenia Scale (CGI-SCH), a simple instrument,
appropriate for use in observational studies (20). The researchers
who developed this instrument, reported that the correlation
coefficient between the CGI-SCH for positive symptoms and
the PANSS score was 0.86 and the interrater reliability was high
(intraclass correlation coefficient, ICC = 0.82). Possible scores
for positive symptoms are “normal, not ill” (1), “minimally
ill” (2), “mildly ill” (3), “moderately ill” (4), “markedly ill” (5),
“severely ill” (6), and “among the most severely ill” (7) (20)
(see Appendix for a more detailed description of the scores).
We defined treatment-resistance of positive symptoms as the
persistence of at least markedly severe positive symptoms (score
5 or higher), despite adequate treatment. Adequate treatment
was defined as having used two different antipsychotics, of
which at least 1 s generation antipsychotic, during at least 4
weeks in an adequate dosage. A list of adequate dosages of
antipsychotic medication (see Appendix) was constructed
using studies on comparable dosages of antipsychotics (21–23),
information from the World Health Organization on Defined
Daily Dosages (24) and Dutch guidelines (18). Three other
indications for clozapine (markedly severe tardive dyskinesia,
aggressive behavior or suicidality, all persisting during the use
of two other antipsychotics) were also elaborated in the decision
tree (5–11).
Procedures
In June 2015, the psychiatrists and nurse practitioners of each
team followed a training in the assessment of an indication
for clozapine, during which the decision tree was introduced.
After the training, the nurse practitioner identified all patients
with NAPD by checking the DSM-IV codes, schizophrenia,
schizophreniform disorder, schizoaffective disorder, or psychotic
disorder not otherwise specified. The latter diagnosis was
included because some Dutch psychiatrists are reluctant to use
the word schizophrenia. In part of the teams, the controversy
surrounding the concept of schizophrenia seems to have led to
an increase of the diagnosis psychotic disorder not otherwise
specified, and a lower use of schizophrenia as diagnostic
label.
Patients with delusional disorder were not included, because
clozapine has not shown to be effective for them. Those
diagnosed with a brief psychotic disorder were also excluded
because clozapine is not indicated for patients with this
diagnosis.
The nurse practitioner of each team, assisted by the first
author, reviewed the files of all the patients treated by that team.
They identified the patients who were already on clozapine or
had used this drug and had discontinued it. We assumed that
all of these patients had an appropriate indication for this drug.
TABLE 1 | Demographic and clinical features of 2,588 patients with Non-Affective Psychotic Disorder, treated by 20 Functional Assertive Community Treatment (FACT)
teams and three Early Intervention teams in the Netherlands, 2016.
Characteristic Total Clozapine, current users (Type 1) Other patients
FACT teams n = 2,286 n = 526 n = 1,760
Mean (SD) Mean (SD) Mean (SD)
Age (years) 46.5 (11.6) 44.9 (10.7) 47.0 (11.9)
Sex, Male 65.9% 68.1% 64.4%
DSM-IV DIAGNOSIS (%) (%) (%)
Schizophrenia (including schizophreniform disorder) 65.0 82.5 58.9
Schizoaffective disorder 15.2 12.9 15.8
Psychotic disorder not otherwise specified 19.8 4.6 25.3
Early intervention teams n = 302 n = 34 n = 268
Mean (SD) Mean (SD) Mean (SD)
Age 33.8(10.1) 29.6(5.9) 34.2(10.4)
Sex, Male 68.9% 79.4% 67.7%
DSM-IV DIAGNOSIS (%) (%) (%)
Schizophrenia (including schizophreniform disorder) 47.3 67.7 44.5
Schizoaffective disorder 6.0 8.8 5.9
Psychotic disorder not otherwise specified 46.7 23.5 49.6
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TABLE 2 | Mean proportion and range of type 1, type 2, type 3, and type 4
patients and results of χ2-tests to compare teams, in 20 Flexible Assertive
Community Treatment (FACT)-teams and 3 Early intervention teams in the
Netherlands, 2016.
% Range χ2 df p
FACT-teams n = 2,286
Type 1 (users) 23.0 8.8–34.7 53.6 19 <0.001*
Type 2 (former users) 3.5 0–8.2 26.75 19 0.110
Type 3 (unfulfilled indication) 6.9 1.7–15.6 55.97 19 <0.001*
Type 4 (as yet insufficiently
treated)
8.6 1.8–16.3 52.29 <0.001*
Total of type 1, 2, and 3 33.4 17.6–47.6 66.97 19 <0.001*
Users among type 1, 2 and
3
68.8 49.0–90.9 46.64 19 <0.001*
Early intervention teams n = 302
Type 1 (users) 11.3 8.5–14.1 1.35 2 0.509
Type 2 (former users) 2.3 1.1–3.6 1.88 2 0.391
Type 3 (unfulfilled indication) 4.6 0–9.4 13.14 2 0.001*
Type 4 (as yet insufficiently
treated)
11.6 7.0–16.3 3.51 2 0.171
Total of type 1, 2, and 3 18.2 11.3–23.7 5.70 2 0.058
Users among type 1, 2,
and 3
61.8 45.5–92.9 10.04 2 0.007
*A p-value of < 0.008 was considered statistically significant.
Next, using the decision tree, the nurse practitioner, again assisted
by the first author, assessed the remaining patients for clozapine
indications, regardless of the feasibility of a trial with clozapine.
These patients were divided into 3 groups: (a) no indication,
(b) indication, and (c) questionable indication (for example a
score of 4 “moderate” on the CGI-SCH or uncertainty about
other indications or previous treatment with antipsychotics)
Subsequently, they discussed the cases from the latter two
categories with the responsible psychiatrist and tried to reach
consensus about the indication for a trial with clozapine. In case
of discordance, the opinion of the psychiatrist was decisive.
Statistical Analysis
Descriptive statistics were used to summarize demographic and
clinical characteristics. χ2-tests were used to compare teams on
all four types of patients.
After a Bonferroni correction for multiple testing, a two-tailed
p-value of <0.008 was considered statistically significant for all
tests.
RESULTS
Demographic and Clinical Characteristics
In the FACT-teams, there were 2,286 patients with NAPD and in
the early intervention teams 302 patients. The characteristics of
these patients are presented in Table 1.
Use of Clozapine
The overall actual clozapine prescription rate among FACT-
and early intervention-teams (type 1 patients) was 21.6%. The
overall proportion of patients with an indication for clozapine
at any time type 1, type 2, and type 3) was 33.4% in FACT-
teams and 18.2% in early intervention-teams (overall: 31.6%). Of
these patients 68.3% was using clozapine (FACT-teams: 68.8%
and early intervention-teams: 61.8%) also with a high variability
between teams, see Table 2.
The proportions of type 1, type 2, type 3, and type 4 patients
and the ranges between teams are shown in Table 2, by type
of team. We found a significant variability between teams with
regard to the proportions of all 4 types of patients (see Figure 1).
The overall rate of underprescription (type 3 patients) was
6.6%. In 94.8% of these patients treatment-resistant positive
symptoms were the reason for the clozapine indication (see for
indications and combinations of indications Table 3). Only 5.2%




The prescription rate of clozapine in FACT- and early
intervention-teams was 21.6% (type 1 patients), and the rate
of underprescription was 6.6% (type 3). However, the latter
proportion is probably higher, because a part of the as yet
insufficiently treated patients (type 4) may turn out to have an
indication for this drug too. The differences between teams in
prescribing and underprescribing clozapine, were very large and
statistically significant.
Interpretation
The proportion of outpatients with NAPD on clozapine in this
study is higher than those reported by other European studies
in outpatients. A national database study in Denmark found
that 10.1% of the patients with a diagnosis of schizophrenia
was using clozapine (15). In a study in France, only 1.2%
of the users of antipsychotics was using clozapine. However,
6.6% of the total population was using antipsychotics, so
the clozapine prescription rate among patients with NAPD
may be much higher (13). Although different study designs
may contribute to these differences, a large international
database study (25) also showed that prescription rates in
the Netherlands are higher than in most other countries. A
national clozapine expertise center, founded in 2004, may have
contributed to this Bogers et al. (26). An audit in the UK,
with a comparable real-world design found similar rates of
23.7% (27). However, Patel et al. only included patients that
were under care for at least 12 months, which may have
led to somewhat higher clozapine prescription rates. They
found a proportion of 21.2% of patients who were not or
partially in remission (no definition given) and were not
prescribed clozapine. Sixty-one percent of these patients had
already received two adequate trials of antipsychotics, suggesting
that 12.9% was having an unfulfilled indication for clozapine.
However, drug adherence had been investigated for only 85% of
them.
We found considerable difference in clozapine prescription
rates between teams which may partly be caused by differences
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FIGURE 1 | Per team: proportions of current users of clozapine, of previous users, of those with an indication for this drug, and of those as yet insufficiently treated to
have a diagnosis of treatment-resistance. The first 20 bars are the FACT-teams, and the last three bars are the early intervention teams.
TABLE 3 | Type of indication for clozapine among 172 patients with Non-Affective
Psychotic Disorder, with an unfulfilled indication, from 20 Flexible Assertive
Community Treatment (FACT)-teams and 3 early intervention teams in the
Netherlands, 2016.
Single indication N = 134 N %
Treatment-resistant positive symptoms 125 72.7
Aggression 1 0.6
Suicidality 3 1.7
Acute extrapyramidal symptoms 3 1.7
Tardive dyskinesia 2 1.2
Multiple indications N = 38
TREATMENT-RESISTANT POSITIVE SYMPTOMS
And aggression 24 14.0
And suicidality 8 4.7
And suicidality + aggression 1 0.6
And extrapyramidal symptoms 2 1.2
And tardive dyskinesia 1 0.6
And extrapyramidal symptoms + tardive dyskinesia 2 1.2
in the severity of psychopathology. However, we also found
significant differences in prescription rates after restricting the
analysis to patients with an indication for this drug. It is
unlikely therefore, that the variability between teams is entirely
explained by differences in severity of psychopathology. Other
explanatory variables are local norms and traditions (13, 28,
29) or specific clinician-related factors, such as their workload,
knowledge and preferences (30). The more the time of the
psychiatrist is restricted, the more difficult it may become to
supervise the weekly blood drawings and monitor adequately for
potentially lethal side-effects. Consequently, extra staff, such as
the deployment of a nurse practitioner, may help in preventing
needless delay in clozapine initiation (31).
Strengths and Limitations
A strength of this study is the large number of patients from
both FACT- and early intervention-teams from four different
institutes. Additionally, we were able to determine the exact
proportion on clozapine and the decision tree allowed for
a standardized method to assess indications for clozapine.
However, several limitations require comment. First, the teams
of this study belonged to institutes that had agreed to participate
in a trial on the safety of the deployment of nurse practitioners
to start patients on clozapine. Consequently, the non-random
selection of teams diminishes the generalizability of the results.
Second, the quality of the information obtained from electronic
files was not optimal in all cases. Some diagnoses may have
been inaccurate and some information on antipsychotics was lost
during the transition from paper file to electronic file, about 10
years ago. Information on the presence of tardive dyskinesia was
often lacking and was almost solely obtained verbally from the
responsible nurse practitioner or psychiatrist. Third, the rating
of the severity of the positive symptoms may not always have
been perfectly valid. However, since there were only 2 cases of
discordance on the indication for clozapine, the decisive role
of the psychiatrist barely influenced the results. Finally, our
definition of treatment-resistance differed somewhat from that in
recently published guidelines (2), in that it was based on a higher
score for the severity of positive symptoms (marked instead of
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moderate), on a adherence of 90% of prescribed antipsychotics
taken (instead of 80%), but on a shorter duration of adequate
treatment (4 instead of 6 weeks) and on a slightly lowerminimum
dosage of antipsychotic drug, see Appendix. Consequently, a
substantial over- or underestimation of the number of indications
for clozapine is highly unlikely.
CONCLUSION
In conclusion, about a third of the Dutch outpatients with
NAPD is indicated for the use of clozapine and more than
two-thirds of them are using it. By international standards, the
clozapine prescription rates in Dutch ambulatory care are high,
but the differences between teams are considerable. Research into
reasons for this variability is urgently needed to develop targeted
interventions.
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